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each of the 5 routes. B. pseudomallei
could be detected in the tissues of IV-
and IP-infected mice earlier and in
higher numbers than in those of
intranasally and orally-infected mice,
despite the fact that all mice received
equal numbers of bacteria. This find-
ing reflects differences in the innate
immune response, depending on the
route of infection. Bacterial numbers
in mice infected by the IV or IP route
reached >106 CFU by day 2 postinfec-
tion, which indicates a failure of the
innate immune response to control
infection, leading to overwhelming
sepsis and death. 
Bacterial loads in tissues after
challenge with a lethal dose of highly
virulent NCTC 13178 did not indicate
any tropism for the lung after
intranasal infection. As early as day 1,
bacterial loads were greatest in the
liver and spleen, not lungs, of
C57BL/6 and BALB/c mice follow-
ing intranasal challenge. This finding
suggests a very early systemic spread
of B. pseudomallei from the lungs to
other organs. 
Bacteria were detected in the
brains of all mice after infection by
either the IV, IP, intranasal, or oral
route. Colonies recovered from the
brains of C57BL/6 mice infected by
the intranasal or oral routes were
mucoid in appearance. In comparison,
bacteria recovered from brains of
C57BL/6 mice that were challenged
by the IV or IProute demonstrated the
characteristic wrinkled shape on
Ashdown agar and may have been a
consequence of the overwhelming
septicemia that spilled over to all
organs. Variation in colonial morphol-
ogy of B. pseudomallei has been doc-
umented previously (8), and biofilm
formation may be an adaptation of B.
pseudomallei that enables it to evade
host immune responses or to survive
within unfavorable environments
(9,10). The variation in colonial mor-
phology on Ashdown agar observed
in bacteria isolated from brains of
C57BL/6 mice infected by the
intranasal or oral route may reflect a
change to biofilm formation of B.
pseudomallei in this tissue. 
In summary, the results of this
study reiterate the validity of the
mouse model for differential suscepti-
bility to B. pseudomallei, regardless of
the route of infection. The data also
emphasize that virulence depends on
the portal of entry of B. pseudomallei.
Researchers should, therefore, be par-
ticularly cautious when comparing
and extrapolating data from studies
that use different methods of infection. 
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*James Cook University, Townsville,
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Bordetella 
pertussis in Adult
Pneumonia
Patients
1
To the Editor: Although B. per-
tussis infection is well-characterized
in children, the epidemiology and
clinical spectrum of pertussis in ado-
1Presented at the Community Acquired
Pneumonia Conference, Deerhurst Resort,
Ontario, Canada, September 10–12, 2003.LETTERS
lescents and adults are less well
defined. Instances of pneumonia com-
plicating adult pertussis have been
reported (1,2), yet the role of B. per-
tussis in adult pneumonia has not
been rigorously evaluated. 
This study searched specifically for
evidence of B. pertussis infection in
304 adults (≥18 years) admitted to
Christchurch Hospital (Christchurch,
New Zealand) with community-
acquired pneumonia from August
1999 to July 2000 (3). Nasopharyn-
geal samples and paired serum sam-
ples from these patients were stored
and later tested for B. pertussis DNA
and  B. pertussis antibodies. Culture
for  B. pertussis was not performed
because B. pertussis was not part of
the original pneumonia study protocol.
Nasopharyngeal samples were
centrifuged and tested for B. pertussis
DNA by using the IS481 hemi-nested
polymerase chain reaction (PCR)
assay described previously (4). Serum
samples taken from the patients during
acute and convalescent phases of dis-
ease were tested for immunoglobulin
(Ig)A and IgG antibodies against B.
pertussis whole cell antigens by using
enzyme-linked immunosorbent assay
(ELISA) (Pan Bio, Queensland,
Australia). All positive serum samples
were tested for pertussis toxin (PT)
IgG antibodies, the most specific sero-
logic marker for recent B. pertussis
infection (5). This assay, which uses
highly purified PTas antigen, has been
described in detail elsewhere (6). 
Of the 304 adults, both acute and
convalescent phase serum samples
were available from 257 patients, only
acute phase samples were available
from 46 patients, and no samples were
available from 1 patient; nasopharyn-
geal swabs samples were available for
testing for 275 patients. Overall, 8
(3%) patients had definite recent B.
pertussis infection based on B. pertus-
sis DNA in nasopharyngeal samples
(8 patients) or elevated levels of anti-
PTIgG antibodies (single sample with
an anti-PT IgG level ≥100 EU/mL, or
demonstration of a ≥4-fold rise in
anti-PT IgG level) (5 patients).
Eighteen (6%) additional patients had
evidence of possible recent B. pertus-
sis infection based on elevated levels
of IgA antibody or demonstrated IgG
antibody seroconversion to whole cell
lysate B. pertussis antigens, but had
low levels of anti-PT IgG antibodies.
A moderate degree of pertussis exist-
ed in the community during the study
period, with 4–73 notifications per
month in the Christchurch region
(population 421,000).
Characteristics of the patients with
evidence of recent B. pertussis infec-
tion are shown in the Table. Other res-
piratory pathogens identified from the
patients with definite recent B. pertus-
sis infection were Streptococcus
pneumoniae (2 patients), Haemo-
philus influenzae (2 patients), respira-
tory syncytial virus (1 patient), and
influenza A virus (1 patient).
Respiratory pathogens identified in
the group with possible recent B. per-
tussis infection were S. pneumoniae
(6 patients), H. influenzae (2 patients),
respiratory syncytial virus (2
patients), influenza A virus (2
patients), Legionella pneumophila (1
patient), adenovirus (1 patient), and
Pseudomonas aeruginosa (1 patient).
No patients died, but 2 were admitted
to the intensive care unit. No clinical
or laboratory variables distinguished
patients with recent evidence of per-
tussis from other patients in the study,
although the former group had higher
proportion of current or ex-smokers
(85% vs. 65%; 95% confidence inter-
val for the difference 5%–35%). 
This study is the first to systemati-
cally search for evidence of B. pertus-
sis infection in adults with communi-
ty-acquired pneumonia.  We found
evidence of recent B. pertussis infec-
tion in 3% of adults admitted to the
hospital with well-defined pneumonia
during a period of increased pertussis
activity, and weaker evidence in an
additional 6%. In comparison, a com-
munity-based study of 122 adults with
respiratory tract infections found
serologic evidence of B. pertussis
infection in 7% of the patients (7).
Other studies have reported that pneu-
monia complicates ≈4% of B. pertus-
sis infections in adults (1,2), with the
disease increasing with age (1). 
B. pertussis infection can be diffi-
cult to diagnose, especially if symp-
toms have been present for many
days, and we may have underestimat-
ed the number of patients with recent
pertussis. However, the combination
of PCR and serologic testing is one of
the most sensitive approaches for
diagnosing pertussis in adolescents
and adults (5). The nasopharyngeal
samples may not have been optimal
for PCR testing because they were
placed in viral transport media and
had already been processed for viral
studies. Although the viral transport
media was not inhibitory to the PCR,
the amount of cellular material may
have decreased after this processing. 
Our findings indicate that a small
proportion of adults admitted to the
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hospital with pneumonia had evi-
dence of recent B. pertussis infection.
In these persons, whether B. pertussis
is a primary or secondary pathogen or
an innocent bystander is not clear.
Further work is needed to clarify the
precise role of B. pertussis in develop-
ing adult pneumonia, the risk factors
for  B. pertussis–associated pneumo-
nia, and the value of specific B. per-
tussis therapy in this setting. These
data will also help inform about the
role of pertussis vaccination in adults. 
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SARS Risk
Perception and
Preventive
Measures,
Singapore and
Japan 
To the Editor: Healthcare workers
accounted for 21% of all cases of
severe acute respiratory syndrome
(SARS) during the 2002–2003 out-
break (1). We studied perceptions of
risk for SARS infection and preven-
tive measures among healthcare work-
ers in Singapore, who handled cases of
SARS and where >41% of the cases
occurred among healthcare workers,
and in Japan, a SARS-free country.
A self-administered questionnaire
was distributed to healthcare workers
in various healthcare settings in
Singapore (n = 15,025) and Japan (n =
9,978) from May to September 2003.
Healthcare workers in Singapore were
from 9 primary healthcare hospitals
and 9 major institutional healthcare
settings, including 3 tertiary hospitals
where cases of SARS occurred among
healthcare workers, 1 specialized
women and children’s hospital, 2
community hospitals, and 2 tertiary
dental centers. In Japan, study partici-
pants were healthcare workers at 7
tertiary-level hospitals distributed
throughout Japan. Four of these are
university-attached, 2 are municipal
hospitals, and 1 is a private hospital.
A total of 10,511 (70% response)
and 7,282 (73% response) valid ques-
tionnaires were returned in Singapore
and Japan, respectively. A total of
43% and 45% of the healthcare work-
ers in Singapore and Japan were nurs-
es; others were doctors, physiothera-
pists, pharmacists, attendants, clean-
ing staff, and administrative or cleri-
cal staff. In terms of sociodemograph-
ic characteristics, the mean ages of the
healthcare workers were 36.6 years in
Singapore and 35.6 years in Japan,
while the gender distribution was
82% female in Singapore and 70%
female in Japan, respectively.
Approximately half (57% and 45%,
respectively) of healthcare workers in
Singapore and Japan were married.
A similar proportion (about two
thirds) of healthcare workers in both
countries felt at great risk of exposure
to SARS. However, a higher propor-
tion (76%) was afraid of contracting
SARS in Singapore as compared to
Japan (55%). Nearly all healthcare
workers (96%) in Singapore felt that
implementation of protective meas-
ures at work was generally effective,
and 95% were satisfied with the
explanation of their necessity and
importance. Slightly fewer (93%)
agreed that clear policies and proto-
cols for everyone to follow were in
place. In contrast, among Japanese
healthcare workers, only 65% agreed
that clear policies and protocols were
in place, and many fewer (31%) felt
that protective measures at work were
generally effective (Table).
As to the national experiences with
the SARS outbreak, healthcare work-